Maekawa S - Search Results

1

Safety and Effectiveness of Molnupiravir in Japanese Patients with COVID-19: Final Report of Post-marketing Surveillance in Japan.

Shinozaki S, Watanabe A, Kimata M, Miyazaki M, Maekawa S. Shinozaki S, et al. Among authors: maekawa s. Infect Dis Ther. 2024 Jan;13(1):189-205. doi: 10.1007/s40121-023-00915-w. Epub 2024 Jan 17. Infect Dis Ther. 2024. PMID: 38233606 Free PMC article.

2

Long-Term Safety and Efficacy of Sitagliptin for Type 2 Diabetes Mellitus in Japan: Results of a Multicentre, Open-Label, Observational Post-Marketing Surveillance Study.

Yoshikawa K, Tsuchiya A, Kido T, Ota T, Ikeda K, Iwakura M, Maeda Y, Maekawa S. Yoshikawa K, et al. Among authors: maekawa s. Adv Ther. 2020 May;37(5):2442-2459. doi: 10.1007/s12325-020-01293-2. Epub 2020 Apr 18. Adv Ther. 2020. PMID: 32306246 Free PMC article.

3

Safety and Effectiveness of Letermovir in Allogenic Hematopoietic Stem Cell Transplantation Recipients: Interim Report of Post-marketing Surveillance in Japan.

Hiraishi I, Ueno R, Watanabe A, Maekawa S. Hiraishi I, et al. Among authors: maekawa s. Clin Drug Investig. 2021 Dec;41(12):1075-1086. doi: 10.1007/s40261-021-01096-5. Epub 2021 Nov 16. Clin Drug Investig. 2021. PMID: 34784011 Free PMC article.

4

Real-world safety and effectiveness of pembrolizumab in Japanese patients with radically unresectable melanoma: An all-case postmarketing surveillance in Japan.

Yamazaki N, Shimizu A, Ozaki M, Hamada M, Takeuchi N, Ito Y, Maekawa S. Yamazaki N, et al. Among authors: maekawa s. J Dermatol. 2022 Nov;49(11):1096-1105. doi: 10.1111/1346-8138.16518. Epub 2022 Jul 27. J Dermatol. 2022. PMID: 35896505 Free PMC article.

5

Safety and Effectiveness of Molnupiravir (LAGEVRIO^®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan.

Kimata M, Watanabe A, Yanagida Y, Kinoshita D, Maekawa S. Kimata M, et al. Among authors: maekawa s. Infect Dis Ther. 2023 Apr;12(4):1119-1136. doi: 10.1007/s40121-023-00782-5. Epub 2023 Mar 16. Infect Dis Ther. 2023. PMID: 36928787 Free PMC article.

6

Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance.

Nishiyama H, Tanaka Y, Hamada M, Ozaki M, Minegishi T, Ito Y, Maekawa S, Yamamoto N. Nishiyama H, et al. Among authors: maekawa s. BMC Cancer. 2023 Jun 20;23(1):565. doi: 10.1186/s12885-023-10930-2. BMC Cancer. 2023. PMID: 37340317 Free PMC article.

7

Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan.

Fukuda M, Hattori J, Ohkubo R, Watanabe A, Maekawa S. Fukuda M, et al. Among authors: maekawa s. Clin Drug Investig. 2024 Jul;44(7):527-540. doi: 10.1007/s40261-024-01376-w. Epub 2024 Jun 27. Clin Drug Investig. 2024. PMID: 38935253 Free PMC article.

8

Effectiveness and safety of pembrolizumab for the treatment of Japanese patients with microsatellite instability-high tumors excluding colorectal cancer: a post-marketing surveillance.

Aoki D, Yamauchi M, Izawa M, Ito Y, Hamada M, Ozaki M, Maekawa S, Muro K. Aoki D, et al. Among authors: maekawa s. Jpn J Clin Oncol. 2025 Aug 3;55(8):901-912. doi: 10.1093/jjco/hyaf064. Jpn J Clin Oncol. 2025. PMID: 40382714 Free PMC article.

9

Real-world outcomes of pembrolizumab monotherapy in non-small cell lung cancer in Japan: A post-marketing surveillance.

Yamamoto N, Kamitani T, Kanda K, Ito Y, Hamada M, Ozaki M, Takeuchi N, Yamada T, Kawano M, Maekawa S, Kato T. Yamamoto N, et al. Among authors: maekawa s. Cancer Sci. 2022 Sep;113(9):3110-3119. doi: 10.1111/cas.15439. Epub 2022 Jun 24. Cancer Sci. 2022. PMID: 35611470 Free PMC article.

10

Adverse events of hepatic function disorder in Japanese patients with radically unresectable or metastatic renal cell carcinoma treated with pembrolizumab plus axitinib: a post-marketing surveillance study.

Oya M, Yasuoka S, Tokudome T, Minegishi T, Hamada M, Ozaki M, Maekawa S, Ito Y. Oya M, et al. Among authors: maekawa s. Int J Clin Oncol. 2025 Jun;30(6):1229-1236. doi: 10.1007/s10147-025-02708-2. Epub 2025 Apr 29. Int J Clin Oncol. 2025. PMID: 40299253 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

880 results

Search Page

Filters